Bellicum Pharmaceuticals, Inc. (BLCM)
After hours:
| Previous close | 0.2950 |
| Open | 0.2813 |
| Bid | 0.2450 x 1000 |
| Ask | 0.2756 x 1200 |
| Day's range | 0.2301 - 0.2900 |
| 52-week range | 0.2300 - 2.2000 |
| Volume | |
| Avg. volume | 97,411 |
| Market cap | 2.448M |
| Beta (5Y monthly) | 1.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1700 |
| Earnings date | 10 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
- Zacks
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
- Zacks
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
- GlobeNewswire
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most
